- Home
- ROCL vs SCYX Comparison
ROCL vs SCYX Comparison
Compare ROCL & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROCL
- SCYX
- Stock Information
- Founded
- ROCL 2020
- SCYX 1999
- Country
- ROCL United States
- SCYX United States
- Employees
- ROCL N/A
- SCYX N/A
- Industry
- ROCL Blank Checks
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- ROCL Finance
- SCYX Health Care
- Exchange
- ROCL Nasdaq
- SCYX Nasdaq
- Market Cap
- ROCL 55.7M
- SCYX 50.3M
- IPO Year
- ROCL 2021
- SCYX 2014
- Fundamental
- Price
- ROCL $9.88
- SCYX $1.01
- Analyst Decision
- ROCL
- SCYX Buy
- Analyst Count
- ROCL 0
- SCYX 1
- Target Price
- ROCL N/A
- SCYX N/A
- AVG Volume (30 Days)
- ROCL 27.4K
- SCYX 182.3K
- Earning Date
- ROCL 01-01-0001
- SCYX 11-06-2024
- Dividend Yield
- ROCL N/A
- SCYX N/A
- EPS Growth
- ROCL N/A
- SCYX N/A
- EPS
- ROCL N/A
- SCYX N/A
- Revenue
- ROCL N/A
- SCYX $8,566,000.00
- Revenue This Year
- ROCL N/A
- SCYX N/A
- Revenue Next Year
- ROCL N/A
- SCYX $405.82
- P/E Ratio
- ROCL N/A
- SCYX N/A
- Revenue Growth
- ROCL N/A
- SCYX N/A
- 52 Week Low
- ROCL $9.85
- SCYX $0.97
- 52 Week High
- ROCL $12.20
- SCYX $3.07
- Technical
- Relative Strength Index (RSI)
- ROCL 4.03
- SCYX 30.15
- Support Level
- ROCL $9.85
- SCYX $1.11
- Resistance Level
- ROCL $12.15
- SCYX $1.25
- Average True Range (ATR)
- ROCL 0.31
- SCYX 0.08
- MACD
- ROCL -1.15
- SCYX -0.02
- Stochastic Oscillator
- ROCL 0.00
- SCYX 9.26
About ROCL Roth CH Acquisition V Co.
Roth CH Acquisition V Co is a blank check company.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.